Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard
therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for
the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with
anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in
the treatment of patients with VL in India.
Phase:
Phase 3
Details
Lead Sponsor:
PATH
Collaborator:
World Health Organization
Treatments:
Amphotericin B Liposomal amphotericin B Paromomycin